ADLAI NORTYE
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.
ADLAI NORTYE
Social Links:
Industry:
Biotechnology Health Care Oncology Pharmaceutical
Founded:
2016-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.en.adlainortye.com
Total Employee:
51+
Status:
Active
Contact:
+86 571 2891 8366
Email Addresses:
[email protected]
Total Funding:
293 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Maps SSL By Default Mobile Non Scaleable Content IPv6 Nginx Microsoft Exchange Online
Similar Organizations
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Aston Sci
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
BiolineRx
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Gankill Pharmaceutical
Gankill Pharma Co., Ltd. is conducting research on cancer treatment drugs using PSMD10.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ruihe Capital
Ruihe Capital investment in Post-IPO Equity - Adlai Nortye
Nippon Kayaku
Nippon Kayaku investment in Post-IPO Equity - Adlai Nortye
Legend Star
Legend Star investment in Series D - Adlai Nortye
Tiange Interactive Holdings
Tiange Interactive Holdings investment in Series D - Adlai Nortye
Guolian Securities
Guolian Securities investment in Series D - Adlai Nortye
TriWise Capital
TriWise Capital investment in Series D - Adlai Nortye
SDIC Fund Management
SDIC Fund Management investment in Series D - Adlai Nortye
WuXi Healthcare Ventures
WuXi Healthcare Ventures investment in Series D - Adlai Nortye
Tigermed
Tigermed investment in Series D - Adlai Nortye
ICBC Asset Management
ICBC Asset Management investment in Series C - Adlai Nortye
Official Site Inspections
http://www.en.adlainortye.com
Unable to get host informations!!!
More informations about "Adlai Nortye"
Adlai Nortye - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number +86 571 2891 8366; Adlai Nortye is a global clinical-stage biopharmaceutical company focused on …See details»
Adlai Nortye Biopharma Co., Ltd. Management Team | Org Chart
Adlai Nortye Biopharma Co., Ltd. employs 46 employees. The Adlai Nortye Biopharma Co., …See details»
Adlai Nortye
Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing …See details»
Adlai Nortye Biopharma Co., Ltd. - SignalHire
Adlai Nortye Biopharma Co., Ltd. is a private company that has been in the industry for 20 …See details»
Adlai Nortye - Craft
Mar 24, 2022 Adlai Nortye has 5 employees across 2 locations and $253 m in total funding,. …See details»
Adlai Nortye Company Overview, Contact Details & Competitors
i. ii. iii. iv. - ir.adlainortye.com
Financial personnel resources, including the budget, organization and quality of personnel …See details»
阿诺医药
阿诺医药是一家临床阶段的全球性生物制药公司，致力于开发差异化、创新性的肿瘤免疫治疗药物，涵盖4款临床阶段及多款 ...See details»
Adlai Nortye Announces Global License-out Agreement with …
And benefit people all over the world. For more information, please visit: www.biotime.cn . …See details»
关于阿诺 - Adlai Nortye
新泽西，美国 高级副总裁、全球药政事务负责人See details»
SEC Filing - Adlai Nortye Limited
Dec 31, 2023 (1) Representing 6,000,000 Class A ordinary shares of the Issuer held by …See details»
Log[uM ] -50 IC50 = 25 nM Log[uM ] - Adlai Nortye
1Aldai Nortye Biopharma Ltd., Hangzhou, China ※[email protected] Abtract # 70181 …See details»
SEC Filing - Adlai Nortye Limited
(4) Representing (a) 2,400,000 Class A ordinary shares of the Issuer held by Yang Lu, and (b) …See details»
Help patients live - Adlai Nortye
We focused on developing differentiated, innovative oncology medicines. We are committed to …See details»
Media - Adlai Nortye
E-mail： [email protected]. Adlai Nortye Announces Global License-out Agreement with …See details»
Yonglin Chen Email & Phone Number | Adlai Nortye USA Inc.
Get Yonglin Chen's email address (y*****@adlainortye.com) and phone number at …See details»
新闻资讯 - Adlai Nortye
May 23, 2024 阿诺医药致力于成为打造“全球新”肿瘤药物的创新型研发企业，为中国乃至全球 …See details»
Multiple potential first and best -in-class preclinical assets with ...
Copy or electronic distribution format)the contents of this presentation, and (ii) the confidential …See details»
Adlainortye Security Rating - SecurityScorecard
View Adlainortye's cyber security risk rating against other vendors' scores. Explore cyber risks, …See details»
AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in ...
Immune evasion is a hallmark of cancer (Hanahan, 2011 [4]. Disease progression of colorectal …See details»